[ad_1]
The European Commission accelerates on the anti-Covid vaccine, with the first availability for member countries scheduled for November, and on universal access to the drug. According to Commission officials Ansa, the first availability of the vaccine known as Oxford is expected in November, on which the Commission has signed a contract that allows member countries to buy 300 million doses with an option for another 100.
In addition, after the guarantee of 400 million euros in support of research for the Covax association, next week the EU Executive and the WHO should launch a new mobilization of resources in favor of the WHO Accelerating Law, created to equal access to the vaccine.
Meanwhile, negotiations with pharmaceutical companies continue, with the Pfizer-BioNtech vaccine talks well advanced and in the final stages. An agreement with the American multinational and German biotechnology would establish a diversified group of six candidate vaccines from the companies that are leading the vaccine trial (AstraZeneca, Johnson & Johnson, Sanofi, CureVac, Moderna and Pfizer) for purchase by Member countries of the EU, but also for donations to lower-middle-income countries or redirection to other European countries.
REPRODUCTION RESERVED © Copyright ANSA
Last update:
[ad_2]
